Switch theme
Sign up to access all valuation multiples
Nippon Shinyaku Co Ltd is a specialty and generic drug manufacturing company. Nippon's research and development activities include a focus on pharmaceuticals, nutraceuticals, safety and pharmacokinetics of drug seeds, genomic drug discovery, and nucleic acid drugs. The company also develops health food ingredients, preservatives, protein preparations, and spices. Nippon considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
1919
2.0K+
LTM Revenue $1.1B
LTM EBITDA $281M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nippon Shinyaku has a last 12-month revenue (LTM) of $1.1B and a last 12-month EBITDA of $281M.
In the most recent fiscal year, Nippon Shinyaku achieved revenue of $1.0B and an EBITDA of $267M.
Nippon Shinyaku expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nippon Shinyaku valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | XXX | $1.0B | XXX | XXX | XXX |
| Gross Profit | $755M | XXX | $673M | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 66% | XXX | XXX | XXX |
| EBITDA | $281M | XXX | $267M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 26% | XXX | XXX | XXX |
| EBIT | $239M | XXX | $229M | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $215M | XXX | $177M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 17% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Nippon Shinyaku's stock price is JPY 3561 (or $24).
Nippon Shinyaku has current market cap of JPY 240B (or $1.6B), and EV of JPY 184B (or $1.3B).
See Nippon Shinyaku trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.6B | XXX | XXX | XXX | XXX | $3.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Nippon Shinyaku has market cap of $1.6B and EV of $1.3B.
Nippon Shinyaku's trades at 1.3x EV/Revenue multiple, and 4.8x EV/EBITDA.
Equity research analysts estimate Nippon Shinyaku's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nippon Shinyaku has a P/E ratio of 7.6x.
See valuation multiples for Nippon Shinyaku and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | 4.5x | XXX | 4.8x | XXX | XXX | XXX |
| EV/EBIT | 5.3x | XXX | 5.7x | XXX | XXX | XXX |
| EV/Gross Profit | 1.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 7.6x | XXX | 9.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 21.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNippon Shinyaku's last 12 month revenue growth is 6%
Nippon Shinyaku's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Nippon Shinyaku's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nippon Shinyaku's rule of X is 40% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Nippon Shinyaku and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | -6% | XXX | 1% | XXX | XXX | XXX |
| Rule of 40 | 32% | XXX | 32% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 44% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nippon Shinyaku acquired XXX companies to date.
Last acquisition by Nippon Shinyaku was XXXXXXXX, XXXXX XXXXX XXXXXX . Nippon Shinyaku acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Nippon Shinyaku founded? | Nippon Shinyaku was founded in 1919. |
| Where is Nippon Shinyaku headquartered? | Nippon Shinyaku is headquartered in Japan. |
| How many employees does Nippon Shinyaku have? | As of today, Nippon Shinyaku has 2.0K+ employees. |
| Is Nippon Shinyaku publicy listed? | Yes, Nippon Shinyaku is a public company listed on TKS. |
| What is the stock symbol of Nippon Shinyaku? | Nippon Shinyaku trades under 4516 ticker. |
| When did Nippon Shinyaku go public? | Nippon Shinyaku went public in 1962. |
| Who are competitors of Nippon Shinyaku? | Similar companies to Nippon Shinyaku include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Nippon Shinyaku? | Nippon Shinyaku's current market cap is $1.6B |
| What is the current revenue of Nippon Shinyaku? | Nippon Shinyaku's last 12 months revenue is $1.1B. |
| What is the current revenue growth of Nippon Shinyaku? | Nippon Shinyaku revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Nippon Shinyaku? | Current revenue multiple of Nippon Shinyaku is 1.1x. |
| Is Nippon Shinyaku profitable? | Yes, Nippon Shinyaku is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Nippon Shinyaku? | Nippon Shinyaku's last 12 months EBITDA is $281M. |
| What is Nippon Shinyaku's EBITDA margin? | Nippon Shinyaku's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Nippon Shinyaku? | Current EBITDA multiple of Nippon Shinyaku is 4.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
